Duelling receptors: Estrogen receptor versus mineralocorticoid receptor in the cardiovascular system

Endocrinology (United States)

Volumn 155, Issue 11, 2014, Pages 4117-4119

  Fuller, Peter J ^a   Young, Morag J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; AMINO ACID; ANGIOTENSIN II; CORTICOSTERONE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYSTEINE; DEOXYCORTICOSTERONE; ENDOTHELIN 1; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SERINE; SMALL INTERFERING RNA; ESTROGEN RECEPTOR;

ADRENAL CORTEX CARCINOMA; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR SYSTEM; ELEVATED BLOOD PRESSURE; ENDOTHELIUM CELL; GENE EXPRESSION; GENE SILENCING; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERALDOSTERONISM; HYPERTENSION; LEUKOCYTE ADHERENCE; LIGAND BINDING; MACROPHAGE; MENOPAUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY HYPERALDOSTERONISM; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; SHORT SURVEY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULITIS; ANIMAL; GENE EXPRESSION REGULATION; HUMAN; PHYSIOLOGY;

ANIMALS; ESTROGENS; GENE EXPRESSION REGULATION; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, ESTROGEN; RECEPTORS, MINERALOCORTICOID;

EID: 84908042418     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1778     Document Type: Short Survey

References (20)

1. Pedram A, Razandi M, O'Mahony F, Lubahn D, Levin ER. Estrogen receptor-β prevents cardiac fibrosis. Mol Endocrinol. 2010;24:2152-2165.
2. Pedram A, Razandi M, Korach KS, Narayanan R, Dalton JT, Levin ER. ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female mice. Endocrinology. 2013;154:4352-4364.
3. Chambliss KL, Wu Q, Oltmann S, et al. Non-nuclear estrogen receptor α signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest. 2010;120:2319-23130.
4. Young MJ, Rickard AJ. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol. 2012;350:248-255.
5. Catena C, Colussi G, Sechi LA. Aldosterone, organ damage and dietary salt. Clin Exp Pharmacol Physiol. 2013;40:922-928.
6. Mentz RJ, Bakris GL, Waeber B, et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013;167:1677-1687.
7. Bienvenu LA, Reichelt ME, Delbridge LM, Young MJ. Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte. Clin Sci (Lond). 2013;125:409-421.
8. Barrett Mueller K, Lu Q, Mohammad NN, et al. Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology. 2014;155:4461-4472.
9. Arias-Loza PA, Hu K, Dienesch C, et al. Both estrogen receptor subtypes, α and β, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension. 2007;50:432-438.
10. Coutinho P, Vega C, Pojoga LH, et al. Aldosterone's rapid, non-genomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action. Endocrinology. 2014;155:2233-2243.
11. Adlanmerini M, Solinhac R, Abot A, et al. Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc Natl Acad Sci USA. 2014;111:E283-E290.
12. Caprio M, Newfell BG, la Sala A, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res. 2008;102:1359-1367.
13. Shibata S, Rinehart J, Zhang J, et al. Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab. 2013;18:660-671.
14. Pippal JB, Yao Y, Rogerson FM, Fuller PJ. Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor. Mol Endocrinol. 2009;23:1360-1370.
15. Caroccia B, Seccia TM, Campos AG, et al. GPER-1 and estrogen receptor-β ligands modulate aldosterone synthesis. Endocrinology. 2014;155:4296-4304.
16. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350:151-162.
17. Fernandes-Rosa FL, Williams TA, Riester A, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension. 2014;64:354-361.
18. Levin ER. G protein-coupled receptor 30: estrogen receptor or collaborator? Endocrinology. 2009;150:1563-1565.
19. Feldman RD, Gros R. Vascular effects of aldosterone: sorting out the receptors and the ligands. Clin Exp Pharmacol Physiol. 2013;40:916-921.
20. Fagart J, Hillisch A, Huyet J, et al. Anew mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932-29940.